Search results for "Whooping cough"

showing 10 items of 47 documents

Analogous IgG subclass response to pertussis toxin in vaccinated children, healthy or affected by whooping cough

2003

The study of antigen specific IgG subclass distribution during disease, or during any other natural or artificial immunisation, can provide useful information on the kind of the immune response and the expected levels of protection. This is particularly true for diseases, such as pertussis in which the mechanisms underlying specific defence are still not completely understood. An investigation was therefore performed to evaluate the IgG subclass response to pertussis toxin (PT) in sera from 89 healthy vaccinated children and 131 vaccinated or unvaccinated children convalescent after a confirmed B. pertussis symptomatic infection. Antibody titres were expressed in arbitrary ELISA units/ml, a…

Bordetella pertussisWhooping CoughEnzyme-Linked Immunosorbent AssayPertussis toxinBordetella pertussisSubclassImmune systemReference ValuesmedicineHumansChildWhooping coughPertussis VaccineGeneral VeterinaryGeneral Immunology and MicrobiologybiologyPublic Health Environmental and Occupational Healthmedicine.diseasebiology.organism_classificationAntibodies BacterialVirologyVaccinationInfectious DiseasesPertussis ToxinImmunoglobulin GHumoral immunityImmunologybiology.proteinMolecular MedicineAntibodyVaccine
researchProduct

Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine.

1994

The safety and immunogenicity of an acellular pertussis vaccine containing the genetically detoxified pertussis toxin PT-9K/129C, filamentous hemagglutinin, and pertactin, together with diphtheria and tetanus toxoids, were compared with those of a whole-cell pertussis component-diphtheria-tetanus vaccine. Four hundred eighty infants were enrolled into this prospective, multicenter, double-blind study. Each infant was randomly given three doses of one of the two vaccines at 2, 4, and 6 months of age. Both local and systemic adverse reactions, reported within 48 hours and 7 days of each injection, were less frequent after the acellular vaccine than after the whole-cell vaccine. The enzyme-lin…

Bordetella pertussisbiologybusiness.industryDiphtheriaFilamentous haemagglutinin adhesinbiology.organism_classificationmedicine.diseasePertussis toxincomplex mixturesVirologyVaccinationVaccino pertosse; immunogenicità; tossina; vaccinazione; bambiniPediatrics Perinatology and Child HealthImmunologymedicinePertussis vaccinePertactinBORDETELLA-PERTUSSISbusinessWhooping coughmedicine.drug
researchProduct

Efficacy of Acellular Pertussis Vaccine in Early Childhood After Household Exposure

1996

Objective. —To evaluate the efficacy of a three-dose primary vaccination with a diphtheria-tetanus tricomponent acellular pertussis vaccine against "typical" pertussis, defined as a spasmodic cough of 21 days or longer with confirmation of Bordetella pertussis infection by culture or serology. Design. —Passive monitoring for suspected first household (index) cases of typical pertussis in six areas in Germany comprising 22 505 children vaccinated with study vaccine at 3, 4, and 5 months of age. Blinded, prospective follow-up of household contacts of index cases for incidence and progression of pertussis. Setting. —Six areas in Germany with a high incidence of pertussis. Subjects. —Four hundr…

Bordetella pertussismedicine.medical_specialtyPediatricsbiologybusiness.industryIncidence (epidemiology)General MedicineEnvironmental exposurebiology.organism_classificationmedicine.diseaseVaccine efficacyVaccinationImmunizationEpidemiologyImmunologyMedicinebusinessWhooping coughJAMA: The Journal of the American Medical Association
researchProduct

Prospective Multinational Study of Pertussis Infection in Hospitalized Infants and Their Household Contacts

2007

Increased incidence of pertussis has been noted among infants too young to be immunized. We studied the disease burden of pertussis in pediatric intensive care units and the source of infection in several Asian, European and Latin American countries.The study was conducted in 7 countries from September 2001 to January 2004. Children1 year of age were enrolled from pediatric intensive care units (PICU) and pediatric wards if they presented with respiratory failure, apnea, bradycardia, or cough accompanied by paroxysms, vomiting, whoop or cyanosis. Household members of pertussis-positive index cases were asked to answer a questionnaire and provide diagnostic specimens.Pertussis was confirmed …

Costa RicaMaleMicrobiology (medical)Pediatricsmedicine.medical_specialtyWhooping CoughTaiwanlaw.inventionlawGermanyIntensive caremedicineHumansDisease burdenWhooping coughFamily CharacteristicsSingaporebusiness.industryIncidence (epidemiology)Infant NewbornInfantmedicine.diseaseIntensive care unitInfectious DiseasesEl NiñoSpainPediatrics Perinatology and Child HealthUruguayPertussis vaccineFemaleContact TracingbusinessBrazilContact tracingmedicine.drugPediatric Infectious Disease Journal
researchProduct

European Sero-Epidemiology Network 2: standardisation of immunoassay results for pertussis requires homogeneity in the antigenic preparations.

2008

A standardisation process, already developed during the earlier European Sero-Epidemiology Network (ESEN) project, was employed with a more robust algorithm to harmonise results of pertussis serological assays performed in 12 European and non-European countries. Initially, results from each country's own assay were compared with those obtained at the reference laboratory by means of an in-house pertussis toxin (PT)-based ELISA: seven countries used in-house or commercial PT-ELISAs; the other countries used assays based on Bordetella pertussis whole cell extracts (WCE) (three countries) or on combined PT-FHA (filamentous haemagglutinin) antigenic preparations (two countries). The WCE assays,…

ESEN (European Sero-Epidemiology Network) Pertussis sero-epidemiology Immunoassay standardisation Pertussis antigenic preparationsBordetella pertussisSettore MED/07 - Microbiologia E Microbiologia ClinicaWhooping CoughPertussis toxinBordetella pertussisSerologyAntigenmedicineSero epidemiologyHumansLow correlationWhooping coughImmunoassayPertussis VaccineAntigens BacterialGeneral VeterinaryGeneral Immunology and Microbiologymedicine.diagnostic_testbiologybusiness.industryPublic Health Environmental and Occupational Healthmedicine.diseasebiology.organism_classificationVirologyAntibodies BacterialEuropeInfectious DiseasesImmunoassayImmunologyCalibrationMolecular MedicinebusinessVaccine
researchProduct

Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.

2005

Abstract German adolescents ( n  = 123) without previous pertussis vaccination, no history of pertussis and low IgG-anti-pertussis-toxin (PT) levels received one dose of the Tdap vaccine Boostrix™. Blood samples were taken before, and 5–12 days and 29–49 days after vaccination. IgG- and IgA-anti-PT, IgG- and IgA-anti filamentous hemagglutinin, IgG-anti-pertactin, IgG-anti-tetanus-toxin, and IgG-anti-diphtheria-toxin were measured by ELISA. 88.6% of subjects had an immune response to PT, and all vaccinees had an immune response to at least one pertussis antigen 29–49 days after vaccination. IgA-anti-PT and IgA-anti-FHA responses were found in 43 and 81% of subjects, respectively. This study …

MaleAdolescentWhooping CoughFilamentous haemagglutinin adhesinDiphtheria-Tetanus-acellular Pertussis VaccinesBordetella pertussisImmune systemAntigenImmunitymedicineHumansWhooping coughImmunization ScheduleAntigens BacterialGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityPublic Health Environmental and Occupational Healthmedicine.diseaseVirologyAntibodies BacterialVaccinationInfectious DiseasesImmunoglobulin GImmunologyMolecular MedicineFemalebusinessAcellular pertussisVaccine
researchProduct

Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis …

2001

ABSTRACT The aim of this study was to compare pertussis-specific humoral and cellular immunity in children 5 years after a primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine (DTaP-HBV; InfanrixHepB; SmithKline Beecham) with immunity after natural infection. The subjects were 38 children aged 5 to 6 years who received DTaP-HBV at 3, 5, and 11 months of life and 21 subjects of similar ages and sex who acquired pertussis in the first year of life. Immunoglobulin G (IgG) antibody titers against Bordetella pertussis antigens, peripheral blood mononuclear cell-specific proliferation, and the secretion of cytokines were evaluated. Aft…

MaleBordetella pertussisCellular immunityTime FactorsHepatitis B vaccineWhooping CoughImmunologyMicrobiologyBordetella pertussisAntibodiesInterferon-gammaImmunitymedicineHumansHepatitis B VaccinesSingle-Blind MethodVaccines CombinedLymphocytesChildPreschoolDiphtheria-Tetanus-Pertussis VaccineWhooping coughHaemophilus VaccinesVaccinesbiologyVaccines; Combined; Interferon-gamma; Humans; Whooping Cough; Hepatitis B Vaccines; Child; Lymphocytes; Diphtheria-Tetanus-Pertussis Vaccine; Vaccination; Preschool; Bordetella pertussis; Single-Blind Method; Interleukin-2; Antibodies; Bacterial; Haemophilus Vaccines; Interleukin-4; Interleukin-5; Time Factors; Male; Female; Cell DivisionCombinedTetanusbusiness.industryDiphtheriaCELL-MEDIATED-IMMUNITYVaccinationBacterialbiology.organism_classificationmedicine.diseaseAntibodies BacterialVirologyVaccinationInfectious DiseasesChild PreschoolMicrobial Immunity and VaccinesImmunologyInterleukin-2FemaleParasitologyInterleukin-4Interleukin-5businessCell Division
researchProduct

Reactogenicity of a three-dose pertussis acellular vaccine catch-up in children 21-40 months of age

1999

Abstract The reactogenicity of a three-dose catch-up acellular pertussis (aP) immunization of children at 21–40 months of age was evaluated. Vaccination was well-tolerated: fever ≥38°C was reported after 5% of administered doses and local reactions after 14–15%. The onset of adverse events was not associated with age at vaccination, interval between doses or previous presence of antibodies against pertussis, whereas injection in sites other than the buttock and presence of the same symptom after a previous dose were associated with higher reactogenicity. Because of the good safety profile of primary aP immunization in children >1 year of age, catch-up vaccination campaigns could be consider…

MaleBordetella pertussisPediatricsmedicine.medical_specialtyAgingDose-Response Relationship ImmunologicBordetella pertussisMedicineHumansAdverse effectWhooping coughImmunization SchedulePertussis VaccineReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthInfantbiology.organism_classificationmedicine.diseaseAntibodies BacterialVaccinationInfectious DiseasesImmunizationEl NiñoChild PreschoolImmunoglobulin GToxicityImmunologyMolecular MedicineFemalebusiness
researchProduct

Detection of delayed vaccinations: a new approach to visualize vaccine uptake

2002

For the prevention of pertussis and invasive Haemophilus influenzae type b (Hib) infections, each with a peak for mortality and serious complications in the first year of life, early vaccination is important and needs adequate monitoring. In a 1999 national coverage survey the timing of uptake of these vaccines in German children was therefore assessed conventionally at defined age thresholds and with a new adaptation of the Kaplan–Meier (KM) method estimating immunization uptake over time by 1 minus the survival function s(t). Only 6% and 9% of children were vaccinated against pertussis and Hib in accordance with the national recommended primary vaccination schedule. Coverage levels for th…

MaleBordetella pertussisPediatricsmedicine.medical_specialtyHaemophilus InfectionsTime FactorsWhooping CoughEpidemiologyHaemophilus influenzae typePrimary vaccinationFirst year of lifemedicine.disease_causeHaemophilus influenzaeGermanymedicineHumansImmunization ScheduleWhooping coughHaemophilus VaccinesPertussis VaccinebiologyImmunization Programsbusiness.industryInfant NewbornInfantmedicine.diseasebiology.organism_classificationHealth SurveysVaccinationInfectious DiseasesImmunizationPopulation SurveillanceImmunologyFemalebusinessResearch ArticleEpidemiology and Infection
researchProduct

Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term…

2002

Abstract Immunoglobulin G (IgG) antibody titres against pertussis antigens, Bordetella pertussis-specific proliferation and cytokine production by peripheral blood mononuclear cells (PBMCs) were evaluated at the age of 5–6 years in 13 children who had been pre-term infants with a gestational age (GA) of ≤31 weeks, 10 who had been pre-term infants with a GA of 32–37 weeks, and 15 who had been term infants with a GA of 38–42 weeks. All of the infants had been immunised with a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine (DTaP–HBV) at 3, 5, and 11 months of post-natal age. Our results show that the long-term immune responses induced by primary pertussi…

MaleCellular immunityBordetella pertussisTime FactorsHepatitis B vaccineWhooping CoughImmunization SecondaryIn Vitro TechniquesLymphocyte ActivationBordetella pertussisPertussismedicineHumansHepatitis B VaccinesChildDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleWhooping coughHaemophilus VaccinesImmunity CellularPre-term infantsGeneral VeterinaryGeneral Immunology and MicrobiologybiologyTetanusbusiness.industryDiphtheriaDTaP-HBV vaccine; Pertussis; Pre-term infantsAge FactorsInfant NewbornPublic Health Environmental and Occupational Healthmedicine.diseasebiology.organism_classificationAntibodies BacterialVaccinationInfectious DiseasesCase-Control StudiesChild PreschoolImmunoglobulin GImmunologybiology.proteinDTaP-HBV vaccineCytokinesMolecular MedicineFemaleAntibodybusinessInfant PrematureVaccine
researchProduct